

LOTTE HOLDINGS Japan Invests in Elixiron Immunotherapeutics

LOTTE HOLDINGS CO., LTD. (Headquarter: Tokyo, Japan, President and CEO: Genichi Tamatsuka, hereinafter “LOTTE HOLDINGS”) is pleased to announce a strategic investment in the Series B-2 of Elixiron Immunotherapeutics through its Healthcare and Biopharmaceutical Corporate Venture Capital (“HB-CVC”).

Elixiron Immunotherapeutics (“Elixiron”), a clinical-stage biotechnology company founded in 2017, is advancing a pipeline of first- and best-in-class therapies focused on immune modulation. Its two lead programs are Indemakitug[®] and Enrupatinib[®].

About Indemakitug[®]:

Indemakitug[®] is a first-in-class anti-IFN- γ monoclonal antibody being developed for the treatment of vitiligo^{*1} and hemophagocytic lymphohistiocytosis (HLH), with a Phase II proof-of-concept trial scheduled to start in late 2025.

*1 Vitiligo is a chronic autoimmune skin disease affecting approximately 70 million people worldwide, without FDA-approved systemic treatment option. Indemakitug[®] that targets a clinically validated target for vitiligo treatment, has shown favorable pharmacokinetics and safety profile in Phase I trials.

About Enrupatinib[®]

Enrupatinib[®] is a brain-penetrant CSF-1R inhibitor in Phase II clinical trial for Alzheimer’s disease^{*2}, with top-line data expected in late 2026.

*2 Enrupatinib[®] is expected to be a new disease-modifying therapy for Alzheimer’s disease aimed at suppressing neuroinflammation and improving cognitive function. Its differentiated approach targeting a specific-type of immune cell in brain holds the potential to transform future treatments for neurodegenerative diseases.

LOTTE HOLDINGS established HB-CVC in August 2024 to support innovative startups working on the development of biopharmaceuticals, next-generation antibody drugs, and therapies as part of its new growth business strategy in the healthcare and biopharmaceutical fields. By investing in Elixiron Immunotherapeutics, which is developing innovative treatments for vitiligo and Alzheimer’s disease, LOTTE HOLDINGS aims to address significant unmet medical needs and contribute to improving people’s well-being and creating a healthier society through advanced

medical solutions.

About LOTTE HOLDINGS CO., LTD. (<https://lotte-hd.com/>)

Company Name	LOTTE HOLDINGS CO., LTD.
Headquarters	3-20-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
Representative Director	Genichi Tamatsuka
Website	https://lotte-hd.com/
CVC Website	https://lotte-hd.com/en/business/lifescience/bio-cvc/

Starting with its core confectionery and ice cream businesses, LOTTE HOLDINGS has expanded into a wide range of business fields, including professional baseball team management, real estate, finance, corporate venture capital, hotels, and healthcare. Looking ahead, LOTTE HOLDINGS aims to drive further innovation in its core food business while pursuing new growth opportunities by leveraging business synergies between Japan and South Korea.

The LOTTE Group began its operations in 1948 with the manufacturing and selling of chewing gum in Tokyo, Japan. Today, with headquarters in both Japan and South Korea, the LOTTE Group operates across more than 30 countries and regions worldwide, spanning businesses including food, retail, finance, biopharmaceuticals, healthcare, data centers, hotels and resorts, entertainment, and construction. Guided by its vision as a "Lifetime Value Creator," the LOTTE Group is committed to delivering sustainable value throughout every moment of people's lives.

About Elixiron Immunotherapeutics

Founded in 2017, Elixiron Immunotherapeutics is a clinical-stage biotechnology company focused on developing next-generation precision immunotherapies for autoimmune and neurodegenerative diseases. With operational offices in Taipei and Boston, Elixiron leverages proprietary platforms to develop innovative biologics and small molecules. Its clinical assets include Enrupatinib for Alzheimer's disease and Indemakitug for vitiligo and other immune disorders. Backed by international investors and driven by a mission to harness the immune system's full potential, Elixiron is

advancing therapies that address significant unmet medical needs.

For more information, visit <https://www.elixion.com/> .